Bianca T Hofmann

发表

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

M. Jücker, F. Ewald, A. Grottke, 2014, Investigational New Drugs.

Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma

M. Jücker, F. Ewald, A. Grottke, 2015, Journal of Cancer.

Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.

M. Jücker, F. Ewald, A. Grottke, 2015, Cellular signalling.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

U. Schumacher, Nicole Grabinski, M. Jücker, 2012, Molecular Cancer.

Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.

M. Jücker, B. Hofmann, Bianca T Hofmann, 2012, Cellular signalling.

Beger and Frey procedures for treatment of chronic pancreatitis: comparison of outcomes at 16-year follow-up.

J. Izbicki, J. Erbes, M. Bockhorn, 2014, Journal of the American College of Surgeons.

Frey Procedures for Treatment of Chronic Pancreatitis : Comparison of Outcomes at 16-Year Follow-Up

J. Izbicki, J. Erbes, M. Bockhorn, 2022 .

COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer

H. Schlüter, J. Izbicki, M. Jücker, 2015, Molecular Cancer.

Posttranscriptional regulation of the p85α.alpha; adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells

M. Jücker, E. Mohr, E. Hoxha, 2011, Leukemia & lymphoma.

Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer

C. Betzel, G. Sauter, J. Izbicki, 2020, International journal of cancer.

Loss of complex O-glycosylation impairs exocrine pancreatic function and induces MODY8-like diabetes in mice

P. Steffen, H. Schlüter, J. Izbicki, 2018, Experimental & Molecular Medicine.

Combined targeting of AKT and mTOR using MK‐2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma

K. David, U. Schumacher, Nicole Grabinski, 2013, International journal of cancer.

Pancreatic cancer

C. Güngör, G. Wolters-Eisfeld, B. Hofmann, 2014, British Journal of Pharmacology.

ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer

J. Izbicki, F. Ewald, C. Wagener, 2014, Clinical Cancer Research.

Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α

P. Vogt, Petra Hillmann, J. Hart, 2010, Proceedings of the National Academy of Sciences.